These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 17202365)
1. Targeted antireceptor therapy with monoclonal antibodies leads to the formation of inactivated tetrameric forms of ErbB receptors. Furuuchi K; Berezov A; Kumagai T; Greene MI J Immunol; 2007 Jan; 178(2):1021-9. PubMed ID: 17202365 [TBL] [Abstract][Full Text] [Related]
2. Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains. O'Rourke DM; Qian X; Zhang HT; Davis JG; Nute E; Meinkoth J; Greene MI Proc Natl Acad Sci U S A; 1997 Apr; 94(7):3250-5. PubMed ID: 9096379 [TBL] [Abstract][Full Text] [Related]
3. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion. Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194 [TBL] [Abstract][Full Text] [Related]
4. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. Murali R; Brennan PJ; Kieber-Emmons T; Greene MI Proc Natl Acad Sci U S A; 1996 Jun; 93(13):6252-7. PubMed ID: 8692801 [TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904 [TBL] [Abstract][Full Text] [Related]
6. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682 [TBL] [Abstract][Full Text] [Related]
7. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Ben-Kasus T; Schechter B; Lavi S; Yarden Y; Sela M Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3294-9. PubMed ID: 19218427 [TBL] [Abstract][Full Text] [Related]
8. Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. Qian X; LeVea CM; Freeman JK; Dougall WC; Greene MI Proc Natl Acad Sci U S A; 1994 Feb; 91(4):1500-4. PubMed ID: 7509075 [TBL] [Abstract][Full Text] [Related]
9. The ErbB/HER family of protein-tyrosine kinases and cancer. Roskoski R Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963 [TBL] [Abstract][Full Text] [Related]
10. The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Modjtahedi H; Styles JM; Dean CJ Br J Cancer; 1993 Feb; 67(2):247-53. PubMed ID: 8094290 [TBL] [Abstract][Full Text] [Related]
11. In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Larbouret C; Robert B; Navarro-Teulon I; Thèzenas S; Ladjemi MZ; Morisseau S; Campigna E; Bibeau F; Mach JP; Pèlegrin A; Azria D Clin Cancer Res; 2007 Jun; 13(11):3356-62. PubMed ID: 17545543 [TBL] [Abstract][Full Text] [Related]
12. Recycling of EGFR and ErbB2 is associated with impaired Hrs tyrosine phosphorylation and decreased deubiquitination by AMSH. Meijer IM; van Rotterdam W; van Zoelen EJ; van Leeuwen JE Cell Signal; 2012 Nov; 24(11):1981-8. PubMed ID: 22800866 [TBL] [Abstract][Full Text] [Related]
13. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors. Klapper LN; Vaisman N; Hurwitz E; Pinkas-Kramarski R; Yarden Y; Sela M Oncogene; 1997 May; 14(17):2099-109. PubMed ID: 9160890 [TBL] [Abstract][Full Text] [Related]
14. Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms. Johannessen LE; Haugen KE; østvold AC; Stang E; Madshus IH Biochem J; 2001 May; 356(Pt 1):87-96. PubMed ID: 11336639 [TBL] [Abstract][Full Text] [Related]
15. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Pinkas-Kramarski R; Lenferink AE; Bacus SS; Lyass L; van de Poll ML; Klapper LN; Tzahar E; Sela M; van Zoelen EJ; Yarden Y Oncogene; 1998 Mar; 16(10):1249-58. PubMed ID: 9546426 [TBL] [Abstract][Full Text] [Related]
16. Matuzumab and cetuximab activate the epidermal growth factor receptor but fail to trigger downstream signaling by Akt or Erk. Yoshida T; Okamoto I; Okabe T; Iwasa T; Satoh T; Nishio K; Fukuoka M; Nakagawa K Int J Cancer; 2008 Apr; 122(7):1530-8. PubMed ID: 18033688 [TBL] [Abstract][Full Text] [Related]
17. Identification of p185neu sequences required for monoclonal antibody- or ligand-mediated receptor signal attenuation. Qian X; O'Rourke DM; Drebin J; Zhao H; Wang Q; Greene MI DNA Cell Biol; 1997 Dec; 16(12):1395-405. PubMed ID: 9428788 [TBL] [Abstract][Full Text] [Related]
18. Association of signaling proteins with a nonmitogenic heterodimeric complex composed of epidermal growth factor receptor and kinase-inactive p185c-neu. Dougall WC; Qian X; Miller MJ; Greene MI DNA Cell Biol; 1996 Jan; 15(1):31-40. PubMed ID: 8561895 [TBL] [Abstract][Full Text] [Related]
19. Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Kharmate G; Rajput PS; Watt HL; Somvanshi RK; Chaudhari N; Qiu X; Kumar U Biochim Biophys Acta; 2011 Jun; 1813(6):1172-89. PubMed ID: 21419811 [TBL] [Abstract][Full Text] [Related]